What Tango Therapeutics does

Tango Therapeutics is a clinical-stage biotechnology company developing next-generation precision oncology medicines based on the principle of synthetic lethality. Founded in 2017 and headquartered in Boston, Massachusetts, the company is publicly listed on NASDAQ under ticker TNGX and employs between 101 and 250 people. Tango's core technology is a proprietary CRISPR-based functional genomics target discovery platform that integrates targets, pathways, genetic context and functional data to identify synthetic lethal vulnerabilities in cancers driven by tumor suppressor gene loss or immune evasion. The platform underpins a pipeline of wholly owned, genetically defined drug candidates.

The lead asset is vopimetostat (TNG462), a next-generation MTA-cooperative PRMT5 inhibitor that selectively kills MTAP-deleted cancer cells (preclinical potency 4 nM, 45x selectivity over normal cells). In June 2026 Tango reported a 92% objective response rate for vopimetostat combined with Revolution Medicines' daraxonrasib in MTAP-deleted/RAS-mutant metastatic pancreatic cancer and announced plans for a Phase 3 trial in first-line MTAP-deleted pancreatic cancer. The second clinical PRMT5 inhibitor, TNG456, is a brain-penetrant molecule (potency 20 nM, 55x selectivity) in Phase 1/2 for MTAP-deleted glioblastoma and non-small cell lung cancer. Earlier-stage assets include TNG908 (PRMT5), the discontinued TNG260 co-repressor disruptor, and TNG961, an oral HBS1L molecular glue degrader for FOCAD-deleted cancers disclosed at AACR 2026.

Tango has no commercialized products and does not sell software or services. Revenue is generated entirely from collaboration and licensing agreements with pharmaceutical partners (Revolution Medicines, Erasca, Gilead), and is episodic and milestone-driven — FY2024 revenue was $62.38 million (a 48.3% YoY increase) and Q3 2025 collaboration revenue alone was $53.8 million, while Q4 2025 and Q1 2026 reported zero collaboration revenue. The company funds its operations primarily through equity capital markets, having raised approximately $925M between October 2025 and June 2026 to extend its cash runway into 2028 and to fund late-stage clinical development of vopimetostat.

Name

Tango Therapeutics

Legal name

Tango Therapeutics, Inc.

Website

https://tangotx.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

101–250 employees

Short description

Tango Therapeutics is a clinical-stage biotechnology company that uses a proprietary CRISPR-based functional genomics platform to discover synthetic lethal precision oncology drug candidates, with its lead PRMT5 inhibitor vopimetostat advancing toward Phase 3 in MTAP-deleted pancreatic cancer.

Ownership category

akta.pro rank

Product category

Precision Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

akta.pro secondary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Precision oncology therapeutics
• Synthetic lethality drugs
• PRMT5 inhibitors
• CRISPR drug discovery
• MTAP-deleted cancer therapies

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Collaboration and licensing revenue: Tango Therapeutics generates revenue from collaboration agreements with pharmaceutical partners. Q3 2025 revenue of $53.8M was reported (matching FactSet estimate), while Q4 2025 and Q1 2026 reported zero collaboration revenue, indicating episodic, milestone-driven collaboration receipts rather than recurring revenue. Historical revenue was $5.4M in Q1 2025 and $62.38M for full year 2025 (a 48.3% YoY increase).
2. Equity financing (capital markets): Clinical-stage biotech funded primarily through equity financings including: $80M private placement (Aug 2023, Nextech, Bain Capital Life Sciences), $210M underwritten equity offering + $15M PIPE (Oct 2025, total $225M), $100M ATM facility (Feb 2026, Leerink Partners), $500M public offering launch (June 8, 2026), upsized to $600M (June 10, 2026), and a Boxer Capital $9.5M secondary-market purchase (Feb 2026).

Go-to-market motion3 records

Core offering

Tango Therapeutics is a clinical-stage biotechnology company that discovers and develops precision oncology drug candidates using a proprietary CRISPR-based functional genomics platform focused on synthetic lethality. Its lead asset is Vopimetostat (TNG462), a next-generation MTA-cooperative PRMT5 inhibitor being advanced in Phase 1/2 and toward Phase 3 trials for MTAP-deleted pancreatic and lung cancers, supplemented by TNG456 (brain-penetrant PRMT5 inhibitor), TNG908, and earlier-stage programs.

Product overview

Tango Therapeutics is a clinical-stage biotechnology company that operates a platform-plus-candidates model. The platform — a proprietary CRISPR-based functional genomics target discovery engine — identifies novel synthetic lethal vulnerabilities in cancer cells with specific tumor suppressor gene loss, and feeds a pipeline of wholly-owned precision oncology drug candidates. The lead asset is Vopimetostat (TNG462), an MTA-cooperative PRMT5 inhibitor in Phase 1/2 and heading toward Phase 3 in MTAP-deleted pancreatic cancer; the second clinical PRMT5 inhibitor, TNG456, targets MTAP-deleted glioblastoma and NSCLC with blood-brain barrier penetrance. Earlier-stage and discovery programs include TNG908 (PRMT5 inhibitor), TNG260 (discontinued co-repressor disruptor), and TNG961 (an HBS1L molecular glue degrader for FOCAD-deleted cancers presented at AACR 2026). The portfolio is augmented by clinical collaborations with Revolution Medicines and Erasca, combining vopimetostat with their RAS(ON) inhibitors in MTAP-deleted/RAS-mutant solid tumors.

Differentiator

Problem solved

Functional benefit

Brands

• Vopimetostat (TNG462): Next-generation MTA-cooperative PRMT5 inhibitor in clinical development for MTAP-deleted cancers including pancreatic and lung cancers.
• TNG456
• TNG908
• TNG260
• TNG961

Products and services

• Vopimetostat (TNG462) Next-generation MTA-cooperative PRMT5 inhibitor designed to selectively kill MTAP-deleted cancer cells while sparing normal cells. Demonstrated 45x selectivity and 4 nM potency in MTAP-deleted cells preclinically; advancing into Phase 3 for first-line MTAP-deleted pancreatic cancer based on a 92% ORR in combination with daraxonrasib.
• TNG456 Next-generation blood-brain barrier penetrant MTA-cooperative PRMT5 inhibitor with 55x selectivity and 20 nM potency in MTAP-deleted cells; being developed for MTAP-deleted glioblastoma and non-small cell lung cancer.
• TNG908 Investigational PRMT5 inhibitor evaluated in a clinical trial (NCT05275478) for safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity in patients with MTAP-deleted cancers.
• TNG260 Investigational co-repressor complex disruptor previously evaluated in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors with STK11 loss-of-function mutation and KRAS wild type (NCT05887492). Program discontinued.
• TNG961 Selective, oral HBS1L molecular glue degrader disclosed at AACR April 2026 for the treatment of FOCAD-deleted cancers; currently in discovery/research stage.

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Foghorn Therapeutics: Clinical-stage oncology company targeting chromatin biology, including synthetic-lethal and gene-regulatory mechanisms. Comparable platform-plus-candidates model and clinical stage to Tango.
• Erasca: Clinical-stage precision oncology company developing RAS-pathway inhibitors (including pan-RAS molecular glue ERAS-0015). Active clinical-trial collaborator with Tango on vopimetostat combinations for MTAP-del/RAS-mutant tumors.
• Repare Therapeutics: Clinical-stage precision oncology company using synthetic lethality to develop targeted cancer therapies. Most directly comparable to Tango given shared synthetic-lethal discovery approach and pipeline of genetically defined oncology candidates.
• Revolution Medicines: Clinical-stage oncology company developing RAS(ON) inhibitors including daraxonrasib. Direct strategic partner and combination-trial collaborator with Tango on vopimetostat, while also competing in the broader MTAP-del/RAS-mutant pancreatic cancer space.
• Black Diamond Therapeutics: Clinical-stage precision oncology company using a proprietary discovery platform to develop targeted therapies against oncogenic mutations. Comparable in scale, stage, and genetically defined precision oncology approach.
• Nuvalent: Clinical-stage precision oncology company developing selectively designed kinase inhibitors for genetically defined cancers, including lung cancer programs. Comparable clinical-stage biotech in the precision-oncology and targeted-therapy category.

Emerging players

• Theseus Pharmaceuticals: Clinical-stage oncology company developing targeted kinase inhibitors, including programs addressing resistance mutations. Smaller-scale precision oncology peer with overlapping therapeutic-area focus.
• SpringWorks Therapeutics: Clinical-stage precision oncology company focused on genetically defined cancers and rare tumor types. Comparable clinical-stage peer in targeted oncology with overlapping indication strategy.
• Arvinas: Clinical-stage biotech developing targeted protein degraders (PROTAC and molecular glue degraders). Comparable as Tango also disclosed a molecular glue degrader (TNG961, HBS1L), placing both in the targeted protein degradation and synthetic-lethal oncology space.

Broad incumbents

• Blueprint Medicines: Established commercial-stage precision oncology company developing kinase inhibitors for genomically defined cancers. Broader peer operating at larger scale and with commercial revenue in the same genetically targeted oncology category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/tango-therapeutics
• Xx.com/tango_tx

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds7 records

Investors25 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tango Therapeutics